Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJM112 in moderate to severe chronic hidradenitis suppurativa (phase 2)
2014-004731-39Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing CJM112 arm with Placebo arm (2 arms). Primary endpoint: Clinical responder rate in hidradenitis suppurativa at week 16. Started Feb 2015; status: completed.
02
Drugs
CJM112
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2014-004731-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004731-39.